GPhA Study Assails REMS Misuse to Delay Generics

Drug Industry Daily
Brand manufacturers who use risk evaluation and mitigation strategies (REMS) to delay generic competition by denying product samples to would-be ANDA filers are costing pharmaceutical payers billions of dollars each year, according to a new study commissioned by GPhA.

To View This Article:


Subscribe To Drug Industry Daily